Skip to main content

Advertisement

Table 1 Characteristics and outcome of 112 febrile urinary tract infection occurring among patients with neurogenic bladder depending on treatment duration

From: Management of febrile urinary tract infection among spinal cord injured patients

Treatment duration (days) <10 d 10-15 d >15 d Total P value
Number of febrile UTIa 28 35 49 112  
Patient characteristics      
 Sex (women/men) 12/16 11/24 9/40 32/80 0.2453
 Age: mean year (SD) 49.6 (20.1) 46.5 (24.7) 31 (19.7) 38.4 (11.7) 0.1443
 Fever: mean °C (SD) 38.6 (0.33) 38.9 (0.76) 39.07 (0.78) 38.8 (0.6) 0.5469
 Neurological deficit N (%)      
  Paraplegia 18 (64) 20 (57) 27 (55) 65 (58) 0.2604
  Tetraplegia 5 (18) 2 (6) 13 (27) 20 (18) 0.5205
  Multiple sclerosis 4 (14) 6 (17) 6 (12) 16(14) 0.9299
  Brain injury 1 (4) 7 (20) 3 (6) 11(10) 0.1042
 Voiding management N (%)      
  Intermittent cathererization 14 (50) 13 (37.1) 30 (62) 57 (51) 0.4564
  Indwelling catheter 2 (7) 4 (11) 6 (12) 12 (10) 0.9899
  Reflex voiding 7 (25) 8 (23) 7 (14) 22 (19) 0.8349
  Urinary diversion 2 (7) 6 (17) 3 (6) 11 (10)  
  Others 3 (11) 4 (11) 3 (6) 10 (10)  
Biological variables      
 Leukocyte count: median/L (SD) 12. 9 (5.5) 13 (6.9) 12 (5.7) 12.6 (6) 0.4426
 CRP mean mg/l (SD) 140 (84) 139 (89) 122(90) 121 (84) 0.9953
 Positive blood culture N (%) 3 (10) 5 (14) 9 (18) 17 (15) 0.5246
 Microorganism sample N (%)      
   E coli 17 (53) 16 (37.2) 22 (33) 55 (49)  
   Pseudomonas aeruginosa 6 (18.7) 6 (13.9) 7 (10.6) 19 (13.5)  
   Enterococcus 4 (12.5) 7 (16.2) 8 (12) 19 (13.5)  
   Klebsiella 2 (6.25) 4 (9.3) 8 (12) 14 (10)  
   Proteus 1 (3.12) 3 (7) 4 (6) 8(5.6)  
  Others 2 (6.43) 7 (16.4) 17 (26.4)) 26 (18.4)  
Antibiotic treatment      
 Mean treatment duration (SD) 7.9 (2.3) 13.4 (1.9) 27.3 (9.8) 18.1 (10.7) 0.0250
 Mean parenteral treatment duration (median, SD) 8 (8, ±2.2) 6.8 (5, ±5.33) 11.2 (7, ±10.6) 8.2 (6, ±8.3)  
 Dual therapy N (%) 17 (61) 18 (52) 34 (70) 69 (62) 0.9669
 Antibiotic treatment N (%)      
  Third generation cephalosporin 16 (33) 19 (26.3) 32 (32) 67 (30.6)  
  Aminoglycosides 12 (25) 18 (25) 21 (21) 51 (23.2)  
  Fluoroquinolones 6 (12.5) 14 (19.4) 16 (16) 36 (16.4)  
  Penicillin 9 (18.8) 12 (16.7) 14 (14) 35 (16)  
  Carbapenem 4 (8.3) 5 (6.9) 11 (11) 20 (9.1)  
  Colimycin 1 (2) 2 (2.8) 2 (2) 5 (2.3)  
  Cotrimoxazole 0 0 3 (3) 3 (1.4)  
  Fosfomycin 0 2 (2.8) 0 2 (1)  
Outcome (1 month)      
 Cure N (%) 20 (71.4) 19 (54.2) 28 (57.1) 67 (60.0) 0.3979
 Failure N (%) including: 6 (21.6) 10 (28.5) 15 (30.8) 31 (27.5)  
  Persistence of symptoms 5 (17.8) 9 (25.7) 12 (24.4) 26 (23.2)  
  Death related to UTI 1 (3.5) 1 (3) 3 (6.1) 5 (4.4)  
 Patients who could not be evaluated N (%)b 2 (7.1) 6 (17.1) 6 (12.2) 14 (12.5)  
  Requiring another antibiotic treatment for concomitant infection 0 1 4 5  
  Lost to follow up 1 1 1 3  
  Death unrelated to UTI 1 4 1 6  
 Negative urine culture (D30) N (%) 17 (60.7) 15 (42.8) 21 (42.8) 53 (47.3) 0.635
  1. aUTI = urinary tract infection
  2. bPatients who could not be evaluated: included death unrelated to UTI (n = 6); patients lost to follow-up (n = 3), and patients requiring another antibiotic treatment for a concomitant infection (n = 5)